Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**ST266** is an investigational, cell-free, multi-component secretome biologic developed by Noveome Biotherapeutics. It is manufactured from the soluble factors secreted by cultured human amnion epithelial cells obtained from donated full-term placentas, rather than containing living cells. The product contains physiologic concentrations of hundreds of proteins and other biomolecules, including cytokines and growth factors, intended to promote anti-inflammatory, anti-apoptotic, neuroprotective, reparative, and regenerative effects. ST266 has been evaluated through topical, ophthalmic, intranasal, and intravenous administration in inflammatory, ocular-surface, neurologic, dermatologic, and neonatal diseases. Its active clinical program is a Phase 1/2 study in premature infants with necrotizing enterocolitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ST266.